ADT1219-Epratuzumab Biosimilar-Anti-CD22 mAb-Research Grade

Catalog Number

ADT1219

Product Name

ADT1219-Epratuzumab Biosimilar-Anti-CD22 mAb-Research Grade

Alternate Names

anti-cd22 antibody,  cd22 antibody,  anti cd22 antibody,  human cd22,  anti cd22,  anti-cd22,  anti-mouse cd22 antibody,  recombinant cd22,  anti-cd22 monoclonal antibody,  cd22 antibodies,  cd22 recombinant antibody,  cd22 blocking antibody

Alias

90Y-DOTA-hLL2

Clonity

Monoclonal

Host

CHO Cells

Species

Human

Target

CD22

Gene ID

933

Isotype

IgG1

Size

100ug, 1mg, 5mg

Research Area

Cancer

CAS Number

205923-57-5

Product Description

Epratuzumab is a recombinant,  humanized monoclonal antibody directed against CD22,  a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22,  epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity .

Mechanism of Action

Epratuzumab is a monoclonal antibody targeting CD22,  a molecule expressed on B cells.

Metabolism

Epratuzumab has a long half-life typical of monoclonal antibodies. Its pharmacokinetics involve distribution into the bloodstream and tissues.

Application

IF,  IP,  Neut,  Functional assay,  ELISA,  FC,  ICC,  Activ,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reactivity

Cynomolgus,  Human,  Rhesus Monkey

Reference